1
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams: Compositions and methods for binding sphingosine-1-phosphate. Lpath, BioTechnology Law Group, Daniel M Chambers, November 9, 2010: US07829674 (4 worldwide citation)

The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.


2
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Williams: Methods of using humanized antibodies and compositions for binding sphingosine-1-phosphate. Lpath, Acuity Law Group P C, Daniel M Chambers, September 27, 2011: US08025877 (2 worldwide citation)

The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases ...


3
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams: Compositions and methods for binding sphingosine-1-phosphate. Lpath, Acuity Law Group P C, Daniel M Chambers, September 27, 2011: US08026342 (1 worldwide citation)

The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.


4

5
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams: Humanized antibodies and compositions for binding sphingosine-1-phosphate. Lpath, Acuity Law Group P C, Daniel M Chambers, July 17, 2012: US08222373

The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases ...


6
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams: Nucleic acids coding for humanized antibodies for binding sphingosine-1-phosphate. Lpath, Daniel M Chambers, BioTechnology Law Group, June 7, 2011: US07956173

The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases ...


7
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams: Humanized antibodies and compositions for binding sphingosine-1-phosphate. Lpath, Acuity Law Group P C, Daniel M Chambers, November 29, 2011: US08067549

The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases ...


8
Roger A Sabbadini: Methods for early detection of heart disease. Medlyte Diagnostics, April 3, 2001: US06210976 (174 worldwide citation)

The invention relates to methods, compositions, kits, and devices for detecting cardiac ischemia, hypoxia, or other causes of heart failure in a mammal by obtaining a test sample from a mammal, measuring a level of a non-polypeptidic cardiac marker in the test sample, and determining if the level of ...


9
Roger A Sabbadini: Kits for early detection of heart disease. Medlyte Diagnostics, Richard J Warburg, Foley & Lardner, March 18, 2003: US06534322 (142 worldwide citation)

The invention relates to methods, compositions, kits, and devices for detecting cardiac ischemia, hypoxia, or other causes of heart failure in a mammal by obtaining a test sample from a mammal, measuring a level of a non-polypeptidic cardiac marker in the test sample, and determining if the level of ...


10
Roger A Sabbadini: Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor. Medlyte SDSU Heart Institute, Daniel M Chambers, Biotechnology Law Group, April 19, 2005: US06881546 (24 worldwide citation)

Methods and compositions are disclosed that are useful for the prevention and/or treatment of cardiovascular and cardiac diseases and disorders, or damage resulting from surgical or medical procedures that may cause ischemic or ischemic/reperfusion damage in humans; and cardiovascular trauma. The be ...